Tofacitinib

Tocilizumab Linked to Anemia Marker Improvement in Rheumatoid Arthritis

Tocilizumab Linked to Anemia Marker Improvement in Rheumatoid Arthritis

By

Tocilizumab was associated with significant improvements in hemoglobin and hematocrit over 2 years of treatment in patients with rheumatoid arthritis.

Low Disease Activity in Rheumatoid Arthritis After Tofacitinib Discontinuation

Low Disease Activity in Rheumatoid Arthritis After Tofacitinib Discontinuation

By

Approximately 1 in 3 patients with RA who discontinued tofacitinib maintained low disease activity after 1 year.

Sign Up for Free e-Newsletters